| Literature DB >> 34645877 |
Alyssa Murray1,2, Sujeenthar Tharmalingam1,2,3,4, Phong Nguyen1,2, T C Tai5,6,7,8.
Abstract
Prenatal stress through glucocorticoid (GC) exposure leads to an increased risk of developing diseases such as cardiovascular disease, metabolic syndrome and hypertension in adulthood. We have previously shown that administration of the synthetic glucocorticoid, dexamethasone (Dex), to pregnant Wistar-Kyoto dams produces offspring with elevated blood pressures and disrupted circadian rhythm signaling. Given the link between stress, circadian rhythms and metabolism, we performed an untargeted metabolomic screen on the livers of offspring to assess potential changes induced by prenatal Dex exposure. This metabolomic analysis highlighted 18 significantly dysregulated metabolites in females and 12 in males. Pathway analysis using MetaboAnalyst 4.0 highlighted key pathway-level metabolic differences: glycerophospholipid metabolism, purine metabolism and glutathione metabolism. Gene expression analysis revealed significant upregulation of several lipid metabolism genes in females while males showed no dysregulation. Triglyceride concentrations were also found to be significantly elevated in female offspring exposed to Dex in utero, which may contribute to lipid metabolism activation. This study is the first to conduct an untargeted metabolic profile of liver from GC exposed offspring. Corroborating metabolic, gene expression and lipid profiling results demonstrates significant sex-specific lipid metabolic differences underlying the programming of hepatic metabolism.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34645877 PMCID: PMC8514544 DOI: 10.1038/s41598-021-99598-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Significant results from the untargeted metabolomic screen of liver from female Dex exposed offspring compared to their saline controls. Compounds identified as ** indicate metabolites that reached the two cut-off criteria (p < 0.05 and fold change > 2 or < 0.5) while compounds identifed as * indicate metabolites that reach the p < 0.05 criteria only. Upregulations are presented first in descending order with downregulations following (n = 8).
| Name | Fold change | p value | Description | Pathway(s) |
|---|---|---|---|---|
| 2,3,4,5-Tetrahydroxypentanal** | 6.228 | 1.31E−07 | Heterosaccharide | Upstream of glycerol metabolism |
| Ophthalmic acid** | 4.303 | 3.55E−04 | L-glutamine derivative; analogue of glutathione | Cys and Met metabolism |
| Propionylcarnitine** | 2.059 | 0.0269 | Acylcarnitine; a fatty ester lipid molecule | Lipid/fatty acid (FA) metabolism; lipid transport, oxidation of branched chain FAs |
| Adenosine* | 1.970 | 0.0047 | Component of DNA and RNA; neurotransmitter and potent vasodilator | Purine metabolism; cAMP signaling pathway |
| Adenine* | 1.911 | 0.0109 | Purine nucleobase | Purine metabolism |
| Creatinine* | 1.905 | 0.0012 | Product of creatine phosphate | Arg and Pro metabolism |
| Spermidine* | 1.869 | 8.44E−05 | Polyamine; helps stabilize membranes and nucleic acid structures | Arg, Pro, Ala, and glutathione metabolism; bile secretion |
| Glutathione disulfide* | 1.775 | 0.0416 | Oxidized form of glutathione | Glutathione metabolism |
| Choline* | 1.683 | 0.0221 | Precursor of acetylcholine | Many pathways |
| L-(−)-methionine* | 1.667 | 0.0493 | Essential amino acid | Cys and Met metabolism |
| Hypoxanthine* | 1.634 | 0.0354 | Purine derivative | Purine metabolism |
| L-(+)-Ergothioneine* | 1.558 | 0.0385 | Metabolite of His; antioxidant properties | Histidine metabolism |
| 3-hydroxyisovaleryl carnitine* | 1.486 | 0.0186 | Intermediate of FA oxidation | Lipid/FA metabolism; lipid transport |
| Nicotinamide* | 1.464 | 0.0433 | Pyridine derivative; precursor for NAD + /NADH and NADP + /NADPH | Nicotinate/Nicotinamide metabolism |
| Phosphatidylethanol-amine (18:2/18:2)** | 0.006 | 6.18E-05 | Phosphatidylethanol-amine lipid | Glycerophospholipid metabolism; lipid transport |
| Lactosylceramide (d18:1/12:0)** | 0.216 | 0.0018 | Important ceramide; assists in stabilizing plasma membrane | Phospholipid/ sphingolipid and lipid/FA metabolism; lipid transport |
| Linolenelaidic acid** | 0.308 | 0.0116 | Polyunsaturated omega-6 long chain fatty acid | Lipid/FA metabolism; lipid transport |
| Phosphatidylserine (14:0/14:1)** | 0.491 | 0.0012 | Phosphatidylserine lipid | Glycerophospholipid and lipid metabolism; lipid transport |
Significant results from the untargeted metabolomic screen of liver from male Dex exposed offspring compared to their saline controls. Compounds identified as ** indicate metabolites that reached the two cut-off criteria (p < 0.05 and fold change > 2 or < 0.5) while compounds identified as * indicate metabolites that reach the p < 0.05 criteria only. Upregulations are presented first in descending order while downregulations follow (n = 8).
| Name | Fold change | p value | Description | Pathway(s) |
|---|---|---|---|---|
| Vanillin 4-sulfate** | 3.004 | 0.0035 | Polyphenol metabolite | |
| L-Carnitine tetradecanoyl ester** | 0.203 | 0.0329 | Carnitine with FA attached; beta oxidation of long chain FAs | Lipid metabolism |
| Alpha-aminoadipic acid** | 0.212 | 0.0472 | Intermediate of metabolism of Lys | Lys biosynthesis and degradation |
| PC(18:1(9Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))** | 0.265 | 5.42E-04 | A type of phosphatidylcholine; a glycerophospholipid | Glycerophospholipid/ lipid metabolism |
| LysoPC(18:3(9Z,12Z,15Z))** | 0.355 | 0.0417 | Monoglycerol phospholipid | Phospholipid, lipid and FA metabolism; lipid transport |
| Eicosapentanoic acid** | 0.430 | 0.0486 | Important polyunsaturated fatty acid found in fish oils | Alpha linolenic acid and linoleic acid metabolism; lipid metabolism |
| Uracil** | 0.464 | 0.0405 | Pyrimidine nucleobase | Pyrimidine metabolism; beta-Ala metabolism |
| DL-Carnitine** | 0.487 | 0.0106 | Conditionally essential metabolite; transports fat into mitochondria | Thermogenesis; bile secretion; fatty acid metabolism/β-oxidation |
| Xanthine* | 0.623 | 0.0124 | Intermediate of the degradation of AMP to uric acid | Purine metabolism |
| DL-Tyrosine* | 0.630 | 0.0113 | Essential amino acid; more needed under stress; rapidly metabolized | Cathecholamine biosynthesis; Phe and Tyr metabolism |
| Hypoxanthine* | 0.717 | 0.0406 | Purine derivative; present in anticodon of tRNA | Purine metabolism |
| DL-Tryptophan* | 0.770 | 0.0291 | Essential amino acid; precursor for melatonin and serotonin | Transcription/translation |
Glycerophospholipid general lipid metabolism gene panel RT-qPCR results. mRNA levels in the livers of 19 week old prenatally DEX-exposed offspring relative to saline control. Fold changes in gene expression were calculated by relative quantification (ΔΔCt) of RT-qPCR threshold cycles (Ct) as per Livak and Schmittgen[28] using mean Ct values of housekeeping genes GAPDH and Rpl32. Data is expressed as mean fold change of Dex relative to the saline group ± SEM (n = 8). Unpaired t-test: Statistical significance between groups is shown by: * p < 0.05, ** p < 0.01, *** p < 0.001.
| Gene | Description | Sex | Fold change ± SEM |
|---|---|---|---|
| ACSL1 | Acyl-CoA synthetase | Male Female | 0.93 ± 0.14 1.24 ± 0.16 |
| CRAT | Carnitine acetyl-transferase | Male Female | 0.82 ± 0.13 1.17 ± 0.26 |
| CPT1A | Carnitine palmitoyltransferase 1 | Male Female | 1.18 ± 0.36 2.54 ± 0.28 *** |
| CPT2 | Carnitine palmitoyltransferase 2 | Male Female | 0.91 ± 0.14 1.44 ± 0.19 * |
| ACADL | Acyl-CoA dehydrogenase long chain | Male Female | 0.89 ± 0.15 1.21 ± 0.08 * |
| ACADM | Acyl-CoA dehydrogenase medium chain | Male Female | 0.96 ± 0.12 1.10 ± 0.10 |
| ECH1 | Enoyl-CoA hydratase | Male Female | 1.07 ± 0.14 1.66 ± 0.19 ** |
| HADH | L-hydroxyacyl-CoA dehydrogenase | Male Female | 0.98 ± 0.08 1.23 ± 0.12 * |
| ACAT1 | Thiolase | Male Female | 0.94 ± 0.15 1.15 ± 0.08 * |
| PCCA | Propionyl-CoA carboxylase alpha | Male Female | 0.92 ± 0.05 1.23 ± 0.12 * |
| PCCB | Propionyl-CoA carboxylase beta | Male Female | 0.99 ± 0.09 1.18 ± 0.08 * |
| MCEE | Methylmalonyl-CoA racemase | Male Female | 1.14 ± 0.12 1.26 ± 0.14 * |
| MMUT | Methylmalonyl-CoA mutase | Male Female | 1.01 ± 0.10 1.30 ± 0.12 ** |
| ECI1 | Enoyl-CoA isomerase | Male Female | 0.99 ± 0.27 1.21 ± 0.27 |
| DECR1 | 2,4-dienoyl-CoA reductase | Male Female | 1.00 ± 0.19 1.27 ± 0.14 * |
| PLA1A | Phospholipase A1 | Male Female | 0.97 ± 0.16 1.41 ± 0.18 * |
| PLA2G2A | Phospholipase A2 | Male Female | 1.05 ± 0.07 1.21 ± 0.16 |
| PLCG1 | Phospholipase C | Male Female | 1.10 ± 0.14 1.11 ± 0.12 |
| PLD1 | Phospholipase D | Male Female | 1.09 ± 0.34 1.26 ± 0.34 |
| GDE1 | Glycerophosphodiester phosphodiesterase | Male Female | 0.96 ± 0.15 1.45 ± 0.16 ** |
| PEMT | Phosphatidylethanolamine N-methyltransferase | Male Female | 1.02 ± 0.11 0.97 ± 0.16 |
| PPARA | Peroxisome proliferator-activated receptor alpha | Male Female | 0.87 ± 0.31 1.31 ± 0.33 |
Purine metabolism gene panel RT-qPCR results. mRNA levels in the livers of 19 week old prenatally Dex-exposed offspring relative to saline control. Fold changes in gene expression were calculated by relative quantification (ΔΔCt) of RT-qPCR threshold cycles (Ct) as per Livak and Schmittgen[28] using mean Ct values of housekeeping genes GAPDH and Rpl32. Data is expressed as mean fold change of Dex relative to the saline group ± SEM (n = 8). Unpaired t-test: Statistical significance between groups is shown by: * p < 0.05, ** p < 0.01.
| Gene | Description | Sex | Fold change ± SEM |
|---|---|---|---|
| NT5C2 | 5′-nucleotidase | Male Female | 0.96 ± 0.13 1.19 ± 0.12 |
| ADA | Adenosine deaminase | Male Female | 0.76 ± 0.11 ** 0.79 ± 0.11 ** |
| PNP | Purine nucleoside phosphorylase | Male Female | 1.02 ± 0.08 1.08 ± 0.10 |
| XDH | Xanthine oxidase/dehydrogenase | Male Female | 1.18 ± 0.09 * 1.09 ± 0.13 |
| UOX | Uricase | Male Female | 1.00 ± 0.09 0.89 ± 0.05 * |
Glutathione metabolism gene panel RT-qPCR results. mRNA levels in the livers of 19 week old prenatally Dex-exposed offspring relative to saline control. Fold changes in gene expression were calculated by relative quantification (ΔΔCt) of RT-qPCR threshold cycles (Ct) as per Livak and Schmittgen[28] using mean Ct values of housekeeping genes GAPDH and Rpl32. Data is expressed as mean fold change of Dex relative to the saline group ± SEM (n = 8). Unpaired t-test: Statistical significance between groups is shown by: * p < 0.05.
| Gene | Description | Sex | Fold change ± SEM |
|---|---|---|---|
| GSR | Glutathione reductase | Male Female | 1.19 ± 0.30 1.40 ± 0.22 * |
| GPX1 | Glutathione Peroxidase | Male Female | 0.98 ± 0.21 0.97 ± 0.18 |
| GGT1 | Glutathione hydrolase | Male Female | 1.25 ± 0.18 0.63 ± 0.31 |
| SMS | Spermine synthase | Male Female | 0.96 ± 0.10 1.02 ± 0.12 |
| CAT | Catalase | Male Female | 0.99 ± 0.07 1.08 ± 0.08 |
| SOD1 | Superoxide dismutase 1 | Male Female | 1.05 ± 0.23 0.73 ± 0.20 * |
| SOD2 | Superoxide dismutase 2 | Male Female | 1.05 ± 0.18 0.84 ± 0.14 |
Circadian rhythm gene panel RT-qPCR results. mRNA levels in the livers of 19 week old prenatally Dex-exposed offspring relative to saline control. Fold changes in gene expression were calculated by relative quantification (ΔΔCt) of RT-qPCR threshold cycles (Ct) as per Livak and Schmittgen[28] using mean Ct values of housekeeping genes GAPDH and Rpl32. Data is expressed as mean fold change of Dex relative to the saline group ± SEM (n = 8). Unpaired t-test: Statistical significance between groups is shown by: * p < 0.05.
| Gene | Description | Sex | Fold change ± SEM |
|---|---|---|---|
| CLOCK | Clock circadian regulator | Male Female | 0.88 ± 0.10 0.94 ± 0.19 |
| BMAL1 | Brain and muscle ARNT like protein 1 | Male Female | 0.65 ± 0.42 0.66 ± 0.65 |
| NPAS2 | Neuronal domain PAS protein 2 | Male Female | 0.75 ± 0.49 0.83 ± 0.56 |
| PER1 | Period circadian protein homolog 1 | Male Female | 0.95 ± 0.38 1.59 ± 0.43 |
| PER2 | Period circadian protein homolog 2 | Male Female | 1.56 ± 0.21 * 0.93 ± 0.51 |
| PER3 | Period circadian protein homolog 3 | Male Female | 1.28 ± 0.79 1.23 ± 1.00 |
| CRY1 | Cryptochrome circadian clock 1 | Male Female | 0.83 ± 0.46 1.26 ± 0.26 |
| CRY2 | Cryptochrome circadian clock 2 | Male Female | 1.09 ± 0.15 1.12 ± 0.23 |
| REV-ERBA | Nuclear Receptor Subfamily 1 Group D Member 1 | Male Female | 0.70 ± 1.05 0.66 ± 0.78 |
| METTL3 | N6-adenosine-methyltransferase 70 kDa subunit | Male Female | 1.10 ± 0.14 0.80 ± 0.17 |
| FBXL3 | F-box and leucine rich repeat protein 3 | Male Female | 1.04 ± 0.16 0.92 ± 0.19 |
| CSNK1D | Casein kinase I isoform delta | Male Female | 1.01 ± 0.10 0.92 ± 0.11 |
| CSNK1E | Casein kinase I isoform epsilon | Male Female | 0.78 ± 0.20 1.12 ± 0.44 |
Figure 1Triglyceride concentrations in the liver and plasma of saline and Dex exposed offspring. Levels of triglycerides were measured in the liver (a) and plasma (b) by the Triglyceride Quantification Assay (Abcam) in a colorimetric assay at 570 nm. For the livers, the triglyceride concentration was normalized to the weight of the tissue used for the analysis. The plasma samples were assay directly. The triglyceride concentrations in mM are represented graphically. Statistical significance between saline and Dex groups and sex was determined by one-way ANOVA with a post-hoc Tukey test. Data are presented as mean ± SEM (n = 8). Statistical significance between groups is shown by: * p < 0.05, ** p < 0.01, *** p < 0.001. The * indicates significance when compared to saline female group and the # indicates significance when compared to the saline male group.